Drug discovery

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#AI #Augmented Chemistry #Data #Drug discovery #Pharma

Optibrium publishes study on AI applications in pharma

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets… Read More

#News

#Cancer research #Drug development #Drug discovery #Drug innovation #Oncology #Research #Therapeutics

Sitting down with… Mari Scheiffele, Novartis

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Biopharmaceuticals #Drug discovery #Drug targets

Handbook for the modern antibody development process

The process of antibody discovery and development into a clinical candidate is one full of twists, turns and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated. This eBook released by Twist Biopharma is designed to be used as a… Read More

#News

#CRISPR screening #Drug discovery #Drug screening #Drug targets #Webinar

Webinar: how to achieve rapid translation of targets towards the clinic

Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells… Read More

#News

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#Antigen #Awards #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Winners of ‘The Best Covid-19 Responder’ announced

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In… Read More

#News

#Biosciences #Drug delivery #Drug development #Drug discovery

Charnwood Group acquires Aurelia Bioscience

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Biden to invest US$3 bn to boost Covid-19 drug discovery

As part of the American Rescue Plan, the Biden Administration is investing more than US$3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the whole-of-government strategy to develop the next generation of Covid-19 treatments. Through collaboration within the US Department of Health and Human… Read More

#News #Trending News

#Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Oncology

New oncology research and development collaboration

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More

#News

#CRISPR #Drug discovery #Target validation #Webinar

Join GSK for this exclusive CRISPR-Cas screen event

Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward… Read More

#News

#Cell painting #Drug discovery #Genetics

PerkinElmer’s support creates world’s largest public cell painting dataset

PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium. The consortium, spearheaded by the Broad Institute of MIT and Harvard and including leading pharmaceutical companies and non-profit research organisations, is focused on creating and sharing the world’s largest, public cell imaging… Read More

#News

#Bioscience #Drug development #Drug discovery

Taconic Biosciences launches TruIMPORT importation solution

Taconic Biosciences has launched a new solution, TruIMPORT, for importing genetically engineered models from China into academia vivarium without quarantine, in collaboration with Cyagen. Researchers at non-profit institutions play a critical role in drug discovery; however, outsourcing animal model generation can be cost prohibitive or a logistical challenge. Hurdles in… Read More

#News

#Alzheimer's #Drug development #Drug discovery #FDA #Research

Historic breakthrough in the treatment of Alzheimer’s

The US Food and Drug Administration (FDA) has approved Biogen’s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease, which removes amyloid from brains. Aducanumab is the first new Alzheimer’s drug in nearly 20 years, and there is reportedly mixed evidence over its efficacy. However, according… Read More

#News

#Biology #Biotechnology #Drug development #Drug discovery #Life sciences #SLAS 2021

Poster award deadlines approaching for SLAS 2021

The deadlines for the Tony B. Academic Award and the Student Poster Award for SLAS Europe 2021 is June 14, a week prior to the conference, which takes place June 23-25 digitally. SLAS’ call for poster abstracts provide opportunities to receive recognition, experience and praise for original research by a… Read More

#News

#Covid-19 #Drug discovery

Aspirin does not improve survival for Covid-19 patients

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with Covid-19, who are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly… Read More

#News #Trending News